Concepedia

Jean‐Damien Charrier

JC

Statistics

Publications

13

Citations

1.4K

H-Index

13

Active since

1998

Affiliations

Vertex Pharmaceuticals (United Kingdom)(Current)

University of Sussex

Vertex Pharmaceuticals (United States)

Jean‐Damien Charrier is an author at Vertex Pharmaceuticals (United Kingdom) specializing in life sciences, chemistry, and medicinal chemistry.

Publications per year

1998–2019

13

Publications

13

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

Philip M. Reaper, Matthew R. Griffiths, Joanna Long et al. · Nature Chemical Biology · 2011 · 639 citations

, , +14

Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents

Jean‐Damien Charrier, Steven J. Durrant, Julian M.C. Golec et al. · Journal of Medicinal Chemistry · 2011 · 259 citations · Full text

, , +15

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

Amy B. Hall, Dave Newsome, Yuxin Wang et al. · Oncotarget · 2014 · 195 citations · Full text

, , +16

The discovery of the potent aurora inhibitor MK-0457 (VX-680)

David Bebbington, Hayley Binch, Jean‐Damien Charrier et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 99 citations · Full text

, , +8

Discovery and Structure−Activity Relationship of 3-Aminopyrid-2-ones as Potent and Selective Interleukin-2 Inducible T-Cell Kinase (Itk) Inhibitors

Jean‐Damien Charrier, Andrew T. Miller, David P. Kay et al. · Journal of Medicinal Chemistry · 2011 · 61 citations · Full text

, , +17

1–5 of 13